During the last year, we have seen a significant shift in how countries view medical and recreational cannabis. Over the course of this period, we have watched emerging markets advance and become multi-billion-dollar markets and is a trend that we are bullish on.
Several Canadian Licensed Producers (LPs) have been executing on a multi-national growth strategy and are expanding into the European Union (EU), Latin America, and southeast Asia. Although the growth of the international cannabis market has taken longer than expected, we are favorable on how the industry has advanced.
Tilray, Inc. (NASDAQ: TLRY) is one of the Canadian LPs that has been highly focused on the international cannabis vertical. Once the previously announced mega- merger with Aphria Inc. (APHA.TO) (APHA) is completed, Tilray will be considered to be a leading play on the international cannabis market.
Earlier last week, Tilray reported an important development as it relates to the international cannabis opportunity and received the necessary approvals from New Zealand’s Ministry of Health and the Medicinal Cannabis Agency to launch branded medical cannabis products across the country.
The reason why this is significant is because Tilray was granted the first medical cannabis product approvals according to New Zealand’s new Medical Cannabis Scheme. The rigorous approval process is a testament to the quality of Tilray’s medical cannabis products and we are favorable on this development.
Tilray’s product offering in New Zealand approved under the scheme is centered around its Purified cannabidiol (CBD) products. By the second quarter of 2021, the company expects to have a larger variety of good manufacturing practice (GMP) certified medical cannabis products available for patients.
In addition to supplying hospitals and pharmacies, Tilray has partnered with several leading research institutions to study the effectiveness of medical cannabis as a treatment for a variety of health disorders. From the development of a novel treatment for chemotherapy-induced nausea to a study that examines the effects of driving under the influence of cannabis, Tilray is focused on several major health indications and we are favorable on this.
Tilray is one of the leading providers of medical cannabis in Australia and New Zealand and the first LP to legally export medical cannabis from North America to Australia and New Zealand from its GMP-certified facility in Canada. We are favorable on the strides the business has made on the international side of the industry and expect the mega-merger with Aphria to serve as a major catalyst for growth.
If you are interested in learning more about the countries that Tilray and Aphria are levered to on the international side of the cannabis industry, please send an email to firstname.lastname@example.org with the subject “Tilray and Aphria” to be added to our distribution list.